alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT
32.1





CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER





Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002




I, Keith
A. Meister, Principal Executive Officer of Icahn Enterprises G.P. Inc., the
general partner of Icahn Enterprises L.P. (the “Registrant”), certify that, to
the best of my knowledge, based upon a review of the Icahn Enterprises L.P.,
quarterly report on Form 10-Q for the period ended March 31, 2009 of the
Registrant (the “Report”):




(1) The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended; and




(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Registrant.




/s/
      Keith A. MeisterKeith
      A. MeisterPrincipal
      Executive Officer and Vice Chairman of the
                  Board
      of Icahn Enterprises G.P. Inc.,the
      general
                  partner
      of Icahn Enterprises L.P.


Date: May
6, 2009
§ 1316.42 Definitions. As used in this subpart, the following terms shall have the meanings specified: ( a ) The term *Act* means the Controlled Substances Act (84 Stat. 1242; 21 U.S.C. 801) and/or the Controlled Substances Import and Export Act (84 Stat. 1285; 21 U.S.C. 951).
( b ) The term *Administrator* means the Administrator of the Administration. The Administrator has been delegated authority under the Act by the Attorney General (28 CFR 0.100).
( c ) The term *hearing* means any hearing held pursuant to the Act.
( d ) The term *Hearing Clerk* means the hearing clerk of the Administration.
( e ) The term *person* includes an individual, corporation, government or governmental subdivision or agency, business trust, partnership, association or other legal entity.
( f ) The term *presiding officer* means an administrative law judge qualified and appointed as provided in the Administrative Procedure Act (5 U.S.C. 556).
( g ) The term *proceeding* means all actions involving a hearing, commencing with the publication by the Administrator of the notice of proposed rulemaking or the issuance of an order to show cause.
( h ) Any term not defined in this part shall have the definition set forth in section 102 of the Act (21 U.S.C. 802) or part 1300 of this chapter.
[36 FR 7820, Apr. 24, 1971, as amended at 38 FR 757, Jan. 4, 1973. Redesignated at 38 FR 26609, Sept. 24, 1973, as amended at 62 FR 13969, Mar. 24, 1997; 77 FR 4238, Jan. 27, 2012]
[No. 16091-2-III.

Division Three.

December 11, 1997.]

#### Benton County Mosquito Control District No. 1, et al., *Appellants,*v. Yakima County, et al., *Respondents.*

Appeal from a judgment of the Superior Court for Benton County, No. 95-2-01309-8, Dennis D. Yule, J., entered August 15, 1996. *Affirmed*by unpublished opinion per Kato, J., concurred in by Sweeney, C.J., and Schultheis, J.
<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                              SEP-30-1999
<PERIOD-START>                                 OCT-01-1998
<PERIOD-END>                                   SEP-30-1999
<CASH>                                          20,504,000
<SECURITIES>                                             0
<RECEIVABLES>                                    1,044,000
<ALLOWANCES>                                             0
<INVENTORY>                                      2,614,000
<CURRENT-ASSETS>                                30,325,000
<PP&E>                                          58,033,000
<DEPRECIATION>                                   8,311,000
<TOTAL-ASSETS>                                  88,687,000
<CURRENT-LIABILITIES>                           24,576,000
<BONDS>                                         30,709,000
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                          4,000
<COMMON>                                            76,000
<OTHER-SE>                                      34,095,000
<TOTAL-LIABILITY-AND-EQUITY>                    88,687,000
<SALES>                                                  0
<TOTAL-REVENUES>                                61,488,000
<CGS>                                                    0
<TOTAL-COSTS>                                   55,727,000
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                               1,764,000
<INCOME-PRETAX>                                  4,873,000
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                              4,606,000
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                     4,606,000
<EPS-BASIC>                                         0.62
<EPS-DILUTED>                                         0.52


</TABLE>
. . . .

**‘ .**  OFFICE OF THE A’ ITORNEY GENERAL OF **TEXAS** AUSTIN
§ 514.110 Reasons for refusing to file applications. ( a ) The date of receipt of an application for a new animal drug shall be the date on which the application shall be deemed to be filed.
( b ) An application for a new animal drug shall not be considered acceptable for filing for any of the following reasons: ( 1 ) It does not contain complete and accurate English translations of any pertinent part in a foreign language.
( 2 ) Fewer than three copies are submitted.
( 3 ) It is incomplete on its face in that it is not properly organized and indexed.
( 4 ) On its face the information concerning required matter is so inadequate that the application is clearly not approvable.
( 5 ) The new animal drug is to be manufactured, prepared, propagated, compounded, or processed in whole or in part in any State in an establishment that has not been registered or exempted from registration under the provisions of section 510 of the act.
( 6 ) The sponsor does not reside or maintain a place of business within the United States and the application has not been countersigned by an attorney, agent, or other representative of the applicant, which representative resides in the United States and has been duly authorized to act on behalf of the applicant and to receive communications on all matters pertaining to the application.
( 7 ) The new animal drug is a drug subject to licensing under the animal virus, serum, and toxin law of March 4, 1913 (37 Stat. 832; 21 U.S.C. 151 *et seq.* ). Such applications will be referred to the U.S. Department of Agriculture for action.
( 8 ) It fails to include, with respect to each nonclinical laboratory study contained in the application, either a statement that the study was conducted in compliance with the good laboratory practice regulations set forth in part 58 of this chapter, or, if the study was not conducted in compliance with such regulations, a brief statement of the reasons for the noncompliance.
( 9 ) [Reserved]
( 10 ) The applicant fails to submit a complete environmental assessment under § 25.40 of this chapter or fails to provide sufficient information to establish that the requested action is subject to categorical exclusion under § 25.30 or § 25.33 of this chapter.
( c ) If an application is determined not to be acceptable for filing, the applicant shall be notified within 30 days of receipt of the application and shall be given the reasons therefore.
( d ) If the applicant disputes the findings that his application is not acceptable for filing, he may make written request that the application be filed over protest, in which case it will be filed as of the day originally received.
[40 FR 13825, Mar. 27, 1975, as amended at 50 FR 7517, Feb. 22, 1985; 50 FR 16668, Apr. 26, 1985; 62 FR 40600, July 29, 1997]
**Exhibit
      32(a)**





**Certification
      of Chief Executive Officer Pursuant to 18 U.S.C. § 1350**


**(Section
      906 of the Sarbanes-Oxley Act of 2002)**





Pursuant
      to 18 U.S.C. § 1350, the undersigned officer of Republic Bancorp Inc. (the
“Company”) hereby certifies, to such officer’s knowledge, that the Company’s
      Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2006
      (the
“Report”) fully complies with the requirements of Section 13(a) or 15(d), as
      applicable, of the Securities Exchange Act of 1934 and that the information
      contained in the Report fairly presents, in all material respects, the financial
      condition and results of operations of the Company.








Date:
                May 9, 2006
            /s/
                Dana M. CluckeyName:
                Dana M. CluckeyTitle:
                President and Chief Executive
                Officer





The
      foregoing certification (i) accompanies the filing and is being furnished solely
      pursuant to 18 U.S.C. § 1350, (ii) will not be deemed “filed” for purposes of
      Section 18 of the Securities Exchange Act of 1934, or otherwise subject to
      the
      liability of that section, and (iii) will not be deemed to be incorporated
      by
      reference into any filing under the Securities Act of 1933 or the Exchange
      Act,
      except to the extent that the registrant specifically incorporates it by
      reference.








A
      signed
      original of this written statement required by Section 906, or other document
      authenticating, acknowledging, or otherwise adopting the signature that appears
      in typed form within the electronic version of this written statement required
      by Section 906, has been provided to Republic Bancorp Inc. and will be retained
      by Republic Bancorp Inc. and furnished to the Securities and Exchange Commission
      or its staff upon request.
#### § 522.1696 Penicillin G procaine injectable dosage forms.
Exhibit 99.1

Certification of CEO and CFO Pursuant to  18 U.S.C. Section 1350,  as Adopted Pursuant to  Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report on Form 10-K of Oakley, Inc. (the "Company") for the annual period ending December 31, 2002
as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Jim Jannard, as Chief Executive Officer of the Company, and Tom George, as Chief Financial Officer of the
Company, each hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:



A
signed original of this written statement required by Section 906 has been provided to Oakley, Inc. and will be retained by Oakley, Inc. and furnished to the Securities and
Exchange Commission or its staff upon request.

|/s/JIM JANNARD   |                         | 
|---------------- | ----------------------- | 
|Name:            | Jim Jannard             | 
|Title:           | Chief Executive Officer | 
|Date:            | March 26, 2003          | 
|/s/THOMAS GEORGE |                         | 
|Name:            | Thomas George           | 
|Title:           | Chief Financial Officer | 
|Date:            | March 26, 2002          | 

---

QuickLinks
#### § 332.10 Antiflatulent active ingredients.

Simethicone; maximum daily dose 500 mg. There is no dosage limitation at this time for professional labeling.
#### § 5800.10 What does this part do?

This part adopts the Office of Management and Budget (OMB) guidance in Subparts A through I of 2 CFR part 180, as supplemented by this part, as the U.S. Election Assistance Commission (“the Commission” or “EAC”) policies and procedures for nonprocurement debarment and suspension. It thereby gives regulatory effect for the Commission to the OMB guidance as supplemented by this part. This part satisfies the requirements in section 3 of Executive Order 12549, “Debarment and Suspension” and 31 U.S.C. 6101 note.
§ 500.65 Epinephrine injection 1:1,000 in 10-milliliter containers for emergency treatment of anaphylactoid shock in cattle, horses, sheep, and swine. ( a ) Anaphylactoid reactions in cattle, horses, sheep, and swine occur occasionally from the injection of antibiotics, bacterins, and vaccines. Adequate directions for use of these antibiotics, bacterins, and vaccines can generally be written for use by the laity and thus are available to livestock producers. Epinephrine injection is effective for the treatment of anaphylactoid reactions in animals and would be of value in saving lives of animals if it were readily available at the time of administration of the causative agents. In connection with this problem the Food and Drug Administration has obtained the views of the Advisory Committee on Veterinary Medicine, and other experts, and has concluded that adequate directions for over-the-counter sale of epinephrine injection 1:1,000 can be prepared.
( b ) In view of the above, the Commissioner of Food and Drugs has concluded that it is in the public interest to make epinephrine injection 1:1,000 available for sale without a prescription provided that it is packaged in vials not exceeding 10 milliliters and its label bears, in addition to other required information, the following statements in a prominent and conspicuous manner: “For emergency use only in treating anaphylactoid shock. Usual Dosage: Cattle, horses, sheep, and swine—1 cubic centimeter per 100 pounds of body weight. Inject subcutaneously”.
( c ) The labeling must also bear a description of the symptoms of anaphylactoid shock including glassy eyes, increased salivation, grinding of the teeth, rapid breathing, muscular tremors, staggering gait, and collapse with death following. These symptoms may appear shortly after injection of a bacterin, vaccine, or antibiotic.
Schedule to the form Indemnification Agreement



 Exhibit 10.12 
 SCHEDULE OF PARTICIPATING DIRECTORS AND OFFICERS 
 Armstrong Holdings, Inc. and Armstrong World Industries, Inc. have entered into substantially similar agreements with certain of its directors and officers, including Michael D. Lockhart, H. Jesse Arnelle, James E. Marley, Jerre L. Stead,
Judith R. Haberkorn, John N. Rigas, Stephen J. Senkowski and William C. Rodruan.
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                         580,623
<SECURITIES>                                         0
<RECEIVABLES>                                  166,658
<ALLOWANCES>                                    30,000
<INVENTORY>                                          0
<CURRENT-ASSETS>                               717,281
<PP&E>                                         632,440
<DEPRECIATION>                               (551,577)
<TOTAL-ASSETS>                                 818,144
<CURRENT-LIABILITIES>                        4,736,591
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        81,215
<OTHER-SE>                                  16,469,521
<TOTAL-LIABILITY-AND-EQUITY>                   818,144
<SALES>                                      1,145,219
<TOTAL-REVENUES>                             1,145,219
<CGS>                                                0
<TOTAL-COSTS>                                1,544,289
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           (215,325)
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                 (623,135)
<INCOME-CONTINUING>                              8,740
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     8,740
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>
§ 520.2598 Trilostane. ( a ) *Specifications.* Each capsule contains 5, 10, 30, 60, or 120 milligrams (mg) trilostane.
( b ) *Sponsor.* See No. 043264 in § 510.600 of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* The starting dose is 1.0 to 3.0 milligrams per pound (2.2 to 6.7 milligrams per kilogram) once a day.
( 2 ) *Indications for use.* For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[74 FR 21767, May 11, 2009, as amended at 74 FR 30464, June 26, 2009; 80 FR 53460, Sept. 4, 2015; 87 FR 58962, Sept. 29, 2022]
APHIS Wildlife Services:

Controlling Wildlife Damage on Native 

American Lands

The Wildlife Services (WS) program of 

the U.S. Department of Agriculture’s 

Animal and Plant Health Inspection 

Service (APHIS) is committed to controlling 

damage caused by wild and feral animals. 

APHIS-WS works closely with Native American 

communities to help protect their agricultural 

and natural resources, property, and health 

and safety through cooperative agreements, 

technical and emergency training, outreach 

activities, and consultations that ensure 

APHIS initiatives respect Native American 

cultural heritage and values. 

APHIS-WS may be able to help you:

s Protect livestock from predators like coyotes,

mountain lions, and certain birds

s Reduce damage to property, crops, and

natural resources from feral swine, bears,

beavers, and other wildlife 

s Offer technical guidance and operational

assistance to help indigenous wildlife 

species important to Native American 

communities thrive on Native lands

s Work cooperatively with Native American

communities to manage rabies in wildlife

s Monitor and test for diseases in wildlife

that might be transmitted to livestock

and people such as plague, tularemia,

Rocky Mountain spotted fever, and 

brucellosis

For More Information

Please visit the APHIS Web site at www.aphis.usda.gov for more information 

about our wildlife damage control programs. For specific questions about how 

APHIS-WS can assist your community, please contact WS Staff Officer Lianne 

Hibbert at (301) 851-4011 or lianne.l.hibbert@aphis.usda.gov. 

The U.S. Department of Agriculture is an equal opportunity provider and employer.

Issued September 2012

United States Department of Agriculture

Animal and Plant Health Inspection Service

Program Aid No. 2123-4

s Teach Native American youth and offer work experiences

through APHIS-WS summer internship and training programs

APHIS works closely with Native American communities to 

help protect their agricultural resources.
§ 26.80 Entry into force, amendment, and termination. ( a ) The “Agreement on Mutual Recognition Between the United States of America and the European Community,” from which this part is derived, including its sectoral annexes on telecommunication equipment, electromagnetic compatibility, electrical safety, recreational craft, pharmaceutical Good Manufacturing Practices (GMP) inspections, and medical devices shall enter into force on the first day of the second month following the date on which the parties have exchanged letters confirming the completion of their respective procedures for the entry into force of that agreement.
( b ) That agreement including any sectoral annex may, through the Joint Committee, be amended in writing by the parties to that agreement. Those parties may add a sectoral annex upon the exchange of letters. Such annex shall enter into force 30 days following the date on which those parties have exchanged letters confirming the completion of their respective procedures for the entry into force of the sectoral annex.
( c ) Either party to that agreement may terminate that agreement in its entirety or any individual sectoral annex thereof by giving the other party to that agreement 6-months notice in writing. In the case of termination of one or more sectoral annexes, the parties to that agreement will seek to achieve by consensus to amend that agreement, with a view to preserving the remaining Sectoral Annexes, in accordance with the procedures in this section. Failing such consensus, that agreement shall terminate at the end of 6 months from the date of notice.
( d ) Following termination of that agreement in its entirety or any individual sectoral annex thereof, a party to that agreement shall continue to accept the results of conformity assessment procedures performed by conformity assessment bodies under that agreement prior to termination, unless a regulatory authority in the party decides otherwise based on health, safety and environmental considerations or failure to satisfy other requirements within the scope of the applicable sectoral annex.
Editorial Note on Part 173
Editorial Note: Nomenclature changes to part 173 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; and 81 FR 49896, July 29, 2016.

§ 173.356 Hydrogen peroxide. Hydrogen peroxide (CAS Reg. No. 7722-84-1) may be safely used to treat food in accordance with the following conditions: ( a ) The additive meets the specifications of the *Food Chemicals Codex,* 7th ed. (2010), pp. 496 and 497, which is incorporated by reference. The Director of the Federal Register approves this incorporation by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. You may obtain copies from the United States Pharmacopeial Convention, 12601 Twinbrook Pkwy., Rockville, MD 20852 (Internet address *http://www.usp.org*). Copies may be examined at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( b ) The additive is used as an antimicrobial agent in the production of modified whey (including, but not limited to, whey protein concentrates and whey protein isolates) by ultrafiltration methods, at a level not to exceed 0.001 percent by weight of the whey, providing that residual hydrogen peroxide is removed by appropriate chemical or physical means during the processing of the modified whey.
[76 FR 11330, Mar. 2, 2011, as amended at 81 FR 5592, Feb. 3, 2016; 88 FR 17723, Mar. 24, 2023]